

DORSET MEDICINES ADVISORY GROUP Recommendation Summary

Formerly the Bournemouth, Dorset and Poole Health Technologies Forum, DMAG represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG's clinical commissioning committee (CCC) on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on 18th July 2017. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

PRODUCT	DECISION	COMMENTS
1. Products re-categorised		
Re-categorisation of DOACs for the indication of prevention and treatment of DVT/PE	Approved for use as a "green" drug	A joint application from the Anticoagulation and Cardiovascular Working Group was received to change the traffic light categorisation of all DOACs from "amber" to "green" for the indication of prevention and treatment of DVT/PE was approved.
Re-categorisation of Ezetimibe when used in combination with a statin for the secondary prevention of cardiovascular disease	Approved for use as a "green" drug	A re-categorisation from "amber" to "green", when used in combination with a statin for the secondary prevention of cardiovascular disease, was approved. It will remain as amber for primary prevention in accordance with NICE TA 385
2. New requests		
Methotrexate pre-filled syringes (Nordimet®)	Approved for use as an "amber" drug	A proposal for the addition of Nordimet®, methotrexate pre-filled syringes to be added to the formulary as an "amber with shared care" was approved. Nordimet® as an alternative to Metoject® was considered to be easier for patients to use and slightly more cost-effective in primary care. Patients should be maintained on the product they are initiated/trained on.
Braltus Zonda®	Approved for use as a "green" drug	A formulary proposal for Braltus Zonda® as a first choice option was approved as it was hoped it may provide a cost saving over using Spiriva Handihaler®. The devices were noted to be essentially similar in their mode of use.

PRODUCT	DECISION	COMMENTS
Episenta® for use in bipolar disease	Approved for use as an “amber” drug	The proposal for the addition of Episenta® (sodium valproate) as an “amber drug with shared care guidance was accepted.
Espranor®	Not recommended	Espranor®, an oral lyophilisate formulation of buprenorphine, licensed for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment, to be categorised as not recommended on the Dorset formulary.
3. Products considered by NICE		
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)	Approved	Noted, post meeting, as incorporated within the guideline for the use of biologics in psoriatic arthritis
4. Miscellaneous recommendations by DMAG		
Diabetic Needle Formulary	Approved	A practical reference guide based on adherence to ISO standards considering price and suitability for pen devices was developed by the Diabetes and Endocrinology Working Group and approved by DMAG
Blood Glucose Test Strips Formulary	Approved	A practical reference guide to use which allows for specific features of the different testing strips was approved for use in Dorset.
Vitamin D Guidelines	Approved	Produced by Dr Tristan Richardson were approved by DMAG pending slight amendments to the wording
Primary Care Management of High INR	Approved	Primary Care Management of High INR was developed to support the safe and appropriate management of these patients the guideline will be used by the INR service run by GPs and

PRODUCT	DECISION	COMMENTS
		Dorset Healthcare in the west of the county was approved by DMAG
Dorset COPD treatment guidelines and an asthma summation table to reflect cost-effective first-line choices in each category.	Approved	The updates to clarify cost-effective first-line choices were noted.
Removal of individual commissioning statements for individual inhalers	Approved for removal	commissioning statements for individual inhalers were no longer thought to be helpful and so it was approved that they could be removed from the Dorset Formulary.
RightBreathe website and my mhealth app		Information from the RightBreathe website was noted regarding the various inhalers available and how they are used. A link to this will be added to the formulary. My mhealth app to be investigated as an alternative option.
Guideline for the use of biologics in rheumatoid arthritis	Approved	Updated guideline approved to reflect latest NICE guidance
Guideline for the use of biologics in psoriatic arthritis	Approved	Updated guideline approved to reflect latest NICE guidance
Guideline for the use of biologics in spondyloarthritis including ankylosing spondylitis	Approved	Updated guideline approved to reflect latest NICE guidance
5. Further Assessment / Evidence Required		
A proposal to formalise a shared care arrangement for the provision of long acting antipsychotic injections in primary care, where	Pending	Further exploration of current and potential patient numbers was required to assess the impact on primary care.

PRODUCT	DECISION	COMMENTS
this is in the best interests of the patient.		
6. Expired Documents Reviewed		
Shared Care Guideline for the prescribing and monitoring of Lithium	Approved	The Shared Care Guidelines on the prescribing and monitoring of lithium had been updated using several different reference sources, including NICE. This was approved by DMAG.
Plenadren commissioning statement	Not recommended	Plenadren® tablets contain modified release hydrocortisone. It is licensed for maintenance therapy of adrenal insufficiency in adults, and is given as a once daily (morning) dose. The updated commissioning statement for Plenadren® was noted.

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset

The new traffic light system can be found on the Dorset CCG internet at: [Dorset CCG - Traffic light scheme](#)